Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

GlaxoSmithKline plc (ADR) (GSK): Why You Should Buy This European Healthcare Company

Page 1 of 2

Investors who buy stock in the major pharmaceutical companies likely do so because of several factors, including steady growth, modest valuations, and high dividend yields. A healthcare stock that exhibits all three characteristics can be an investor’s best friend, which is why some of the best performing stocks over the past several decades have come from the pharmaceutical sector.

While most investors probably know the major U.S. industry heavyweights, including Pfizer Inc. (NYSE:PFE) and Eli Lilly & Co. (NYSE:LLY), there’s a European pharmaceutical giant that has a much higher dividend yield than its competitors and may be the best pharmaceutical stock to buy today.

Profits from across the pond

GlaxoSmithKline plc (ADR) (NYSE:GSK)

GlaxoSmithKline plc (ADR) (NYSE:GSK) carries a $122 billion market value and is one of the biggest pharmaceutical companies in the world.

The past few years have been difficult for many pharmaceuticals, as the industry has grappled with slow global economic growth and patent expirations. Those problems are only exacerbated for companies operating in Europe, where the economic conditions remain shaky at best.

That’s why GlaxoSmithKline plc (ADR) (NYSE:GSK)’s most recent annual results, while unimpressive on the surface, show the true resilience of the company. GlaxoSmithKline plc (ADR) (NYSE:GSK)’s business, which is split into Pharmaceuticals, Vaccines, and Consumer Health Care segments, cumulatively saw revenue dip by 1% in the most recent fiscal year.

While that doesn’t sound very good, it compares very favorably to how Pfizer Inc. (NYSE:PFE) and Eli Lilly & Co. (NYSE:LLY) have performed. Pfizer is facing a steep patent cliff as it loses protection on cholesterol drug Lipitor, its best-selling product ever. This is why the company saw full-year sales drop 10%.

Going forward, the picture remains murky at best for Pfizer Inc. (NYSE:PFE). Lipitor accounted for nearly $10 billion in sales in 2011, and you can imagine how difficult it will be to replace those sales. Pfizer is spending heavily on research and development to try to replace that revenue, which will drag down profits in future quarters. That’s why Pfizer management is guiding investors to expect earnings of $1.50 per share to $1.65 per share in fiscal 2013, which would represent a 20% drop from the previous year’s profits.

Eli Lilly is facing its own patent expiration, a major factor behind the company’s 7% decline in full-year 2012 revenue. Eli Lilly & Co. (NYSE:LLY) management is confident in the company’s pipeline, but at the same time, Eli Lilly hasn’t raised its dividend since its February 2009 payout.

Eli Lilly’s 3.8% dividend beats the yield on the broader market, but dividend growth investors understand the merits of a company that can raise its dividend in good times and bad. Management hasn’t indicated when it will next raise its payout, which means dividend growth investors are left out in the cold.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!